IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital (RAVVIH)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main objective of the study is to assess the acceptability of a future therapeutic vaccine against HIV in patients living with HIV-1.
Secondary objectives concern the validation of a specific questionnaire for self-perception and acceptability of therapeutic vaccination against HIV-1 (RAVVIH), the development of a composite score for acceptability based on this questionnaire, and the analysis of critical factors related to: representations of vaccination in general, representations of therapeutic vaccination specific to HIV, perception of disease severity, health-related quality of life, doctor-patient relationship.
| Condition | Intervention |
|---|---|
| HIV | Other: Questionnaire Other: Interview |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital : Multicentric Interventional Study Qualitative and Quantitative |
- VAS scale of acceptability [ Time Frame: For a given participant, study procedure is about 60 minutes. Total period of the study is 12 months. ]
A graduated visual analogue scale (VAS) from 0 (Whatever my situation, I never accept the use of a therapeutic vaccine) to 10 (I totally agree, and I see no problem use a therapeutic vaccine soon there will be one available).
The VAS scale of acceptability is a classic visual analogue scale horizontal scale length 10 cm, graduated from 0 to 10, on which the patient turns his level of agreement with the proposal by a checkmark. The score can then be converted to a 100-point scale to facilitate interpretation of scores.
Which to associate an overall acceptability score compiled from questionnaires.
- score of quality of life [ Time Frame: For a given participant, study procedure is about 60 minutes. Total period of the study is 12 months. ]with the PROQOL-HIV questionnaire
- confidence score of the patient-physician relationship [ Time Frame: For a given participant, study procedure is about 60 minutes. Total period of the study is 12 months. ]with the RAVVIH questionnaire
- perception score of the severity of the disease [ Time Frame: For a given participant, study procedure is about 60 minutes. Total period of the study is 12 months. ]with the Brief IPQ-R questionnaire
| Enrollment: | 220 |
| Study Start Date: | December 2013 |
| Study Completion Date: | December 2014 |
| Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Quantitative study group
Patients complete questionnaires validated and published in the literature: Brief IPQ R and HIV PROQOL [28, 29]. The questionnaire RAVVIH therapeutic vaccine has been designed from the literature review and advice of the Scientific Council in particular Dr. Pierre Verger social scientist vaccination and experts on the perception of patients. It was tested on a sample of 15 PWLHA
|
Other: Questionnaire |
|
Qualitative study group
An interview guide was developed from the literature and expert community. Data will be collected through qualitative interviews with a psychologist trained to conduct interviews. Volunteers will be recruited according to the different categories of people representative of the HIV population in France. These interviews will be conducted at the Foch Hospital. The physician investigator propose participation in the investigation and agree on a day appointment with the psychologist. Consent will be collected at that time after reading the prospectus . All interviews will be recorded orally with the agreement of the participants , and transcribed in full . They will be completely anonymous . The average length of the interviews will be 45-60 minutes. Textual data from these interviews will be analysis. |
Other: Interview |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- infected with HIV-1
- older than 18 and younger than 75 years
- speaking , reading french
- with medical coverage (SS, CMU, AME)
Exclusion Criteria:
- protected adults (adults under guardianship, trusteeship)
- infected with HIV-2
- pregnant women
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT02077101
| France | |
| Centre Hospitalo-Universitaire Louis Mourier | |
| Colombes, Hauts de Seine, France, 92700 | |
| Hopital Foch | |
| Suresnes, Hauts de Seine, France, 92150 | |
| Centre Hospitalier Regional d'Orléans | |
| Orleans, France, 45000 | |
| Principal Investigator: | David Zucman, MD | HOPITAL FOCH Service de Medecine Interne |
More Information
| Responsible Party: | Hopital Foch |
| ClinicalTrials.gov Identifier: | NCT02077101 History of Changes |
| Other Study ID Numbers: |
2013/35 |
| Study First Received: | February 21, 2014 |
| Last Updated: | January 16, 2015 |
Keywords provided by Hopital Foch:
|
HIV Therapeutic vaccine acceptability representations |
Additional relevant MeSH terms:
|
Vaccines Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on July 17, 2017